|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **First author, year** | **Number of patients receiving ITS** | **Mean age** | **Concurrent medical therapy** | **Anaesthetic** | **Injection site** | **Complications** |
| Lyu 2020 | 7 | 31.2 | None | Topical 2% lidocaine | AI or PI | Otalgia 42.9%  Vertigo 14.3% |
| Fu 2019 | 6 | 30.2 | None | Topical lidocaine (unspecified) | PI | No |
| Xu 2019 | 30 | 27.7 | 500mL 10% dextran infusion for 10 days | Topical anaesthesia (unspecified) | PI | No |

*Table 12: Characteristics of studies examining the management of SSNHL in pregnant patients.*